Live webcast Thursday, December 12th at 4:00 p.m. ET
LA JOLLA, California, December 6, 2024 (GLOBE NEWSWIRE) — GRI Bio, Inc. (NASDAQ: GRI) (GRI Bio or the Company), a biotechnology company developing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, announced today that Marc Hertz, PhD, Managing Director of GRI Bio will participate in the Virtual Investor Closing Bell series on Thursday, December 12, 2024 at 4 p.m. ET.
As part of the event, Dr. Hertz will provide company overview and business outlook. In addition to the moderated discussion, investors and interested parties will have the opportunity to ask questions live during the event. The Company will answer as many questions as possible in the allotted time.
A live video webcast will be available on the Events page under the Investors section of the Company's website (gribio.com). A web replay will be available two hours after the live event and will be accessible for 90 days.
About GRI Bio, Inc.
GRI Bio is a clinical-stage biopharmaceutical company aiming to fundamentally change the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio's therapies are designed to target the activity of NKT cells, which are key regulators at the start of the inflammatory cascade, to interrupt disease progression and restore immune system homeostasis. NKT cells are innate-like T cells that share properties of both NK and T cells and provide a functional link between innate and adaptive immune responses. Invariant type 1 (iNKT) cells play a critical role in the propagation of injury, inflammatory response, and fibrosis observed in inflammatory and fibrotic indications. GRI Bio's lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapy for the treatment of idiopathic pulmonary fibrosis, a serious disease with significant unmet need. . The Company is also developing a portfolio of novel NKT type 2 agonists for the treatment of systemic lupus erythematosus. Additionally, with a library of over 500 proprietary compounds, GRI Bio has the capacity to fuel a growing pipeline.
Investor contact:
JTC Team, LLC
Jénène Thomas
(908) 824-0775
GRI@jtcir.com
#GRI #Bio #Participate #Virtual #Investor #Closing #Series #Investing.com
,
